Last month the FDA approved the first treatment for late-stage metastatic melanoma that's shown increased patient survival - Yervoy (ipilimumab). It's also had promising results when combined with chemotherapy in previously untreated patients with inoperable melanoma. However, there is a risk of for severe immune reactions. Read more about the
risks and benefits of Yervoy.
No comments:
Post a Comment